Management of diabetes in elderly patients during the COVID-19 pandemic: current and future perspectives

Expert Rev Endocrinol Metab. 2021 Jul;16(4):181-189. doi: 10.1080/17446651.2021.1927708. Epub 2021 Jun 7.

Abstract

Introduction: The COVID-19 pandemic has affected the entire population with the most deleterious effects in elders. Elders, especially those with diabetes, are at the highest risk of COVID-19 related adverse outcomes and mortality. This is usually linked to the comorbidities that accumulate with age, diabetes-related chronic inflammation, and the pandemic's psychosocial effects.Areas covered: We present some approaches to manage these complicated elderly patients with diabetes during the COVID-19 pandemic. In the inpatient setting, we suggest similar (pre-pandemic) glycemic targets and emphasize the importance of using IV insulin and possible use of continuous glucose monitoring to reduce exposure and PPE utilization. Outside the hospital, we recommend optimal glycemic control within the limits imposed by considerations of safety. We also describe the advantages and challenges of using various technological platforms in clinical care.Expert opinion: The COVID-19 pandemic has lifted the veil off serious deficiencies in the infrastructures for care at both the individual level and the population level and also highlighted some of the strengths, all of which affect individuals with diabetes and COVID-19. We anticipate that things will not return to 'normal' after the COVID-19 pandemic has run its course, but rather they will be superseded by 'New Normal.'

Keywords: COVID-19; diabetes; elderly; hyperglycemia; telemedicine.

Publication types

  • Review

MeSH terms

  • Administration, Intravenous
  • Aged
  • Aged, 80 and over
  • Blood Glucose / analysis
  • Blood Glucose Self-Monitoring / methods
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology
  • COVID-19 / mortality
  • COVID-19 / psychology*
  • Chronic Disease
  • Comorbidity
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / epidemiology
  • Disease Management
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use
  • Inflammation / complications*
  • Insulin / administration & dosage
  • Insulin / therapeutic use
  • Patient Education as Topic / methods
  • Personal Protective Equipment / ethics*
  • Personal Protective Equipment / standards
  • Prevalence
  • Risk Assessment
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / isolation & purification
  • Telemedicine / methods

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin